THE USEFULNESS OF SERUM THYROGLOBULIN IN THE FOLLOW-UP OF DIFFERENTIATED THYROID-CARCINOMA IN CHILDREN

被引:10
作者
KIRK, JMW
MORT, C
GRANT, DB
TOUZEL, RJ
PLOWMAN, N
机构
[1] ST BARTHOLOMEWS HOSP,DEPT RADIOTHERAPY,LONDON EC1A 7BE,ENGLAND
[2] HOSP SICK CHILDREN,DEPT ENDOCRINOL,LONDON WC1N 3JH,ENGLAND
来源
MEDICAL AND PEDIATRIC ONCOLOGY | 1992年 / 20卷 / 03期
关键词
THYROID; CANCER; THYROGLOBULIN; CHILD;
D O I
10.1002/mpo.2950200304
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Serum thyroglobulin has been measured serially in ten children aged 5-17 years presenting with differentiated thyroid carcinoma. At presentation 4 had intra-thyroidal disease, 3 had lymph node metastases, and 3 had lung metastases. During follow-up for a median of 37.0 months (range 21-108) 3 patients have been disease-free, 4 have had a local relapse, and 3 have had persistent disease. Seventy-seven separate serum thyroglobulin measurements have been performed; 36 on and 41 off thyroid replacement therapy. A level of thyroglobulin of < 5 ng/ml was taken as indicative of absence of disease, and compared against combined clinical examination and I-131 scanning. Overall sensitivity of thyroglobulin measurement was 36/37 (97%), and although specificity was 30/40 (75%), this rose to 30/32 (94%) if raised thyroglobulin levels noted within 3 months of I-131 therapy in otherwise asymptomatic patients (n = 4) or in subjects with intact thyroid tissue (n = 4) were excluded. Concordance with clinical status was 30/31 (97%) in measurements taken on, and 31/32 (94%) in those taken off, thyroid replacement. These data indicate that thyroglobulin measurement is a sensitive and specific means of detecting residual, recurrent, and metastatic thyroid carcinoma in children.
引用
收藏
页码:201 / 208
页数:8
相关论文
共 22 条
  • [1] BLACK EG, 1981, LANCET, V2, P443
  • [2] SERIAL SERUM THYROGLOBULIN MEASUREMENTS IN THE MANAGEMENT OF DIFFERENTIATED THYROID-CARCINOMA
    BLACK, EG
    SHEPPARD, MC
    HOFFENBERG, R
    [J]. CLINICAL ENDOCRINOLOGY, 1987, 27 (01) : 115 - 120
  • [3] GIRELLI ME, 1985, EUR J NUCL MED, V10, P252
  • [4] HEDINGER LE, 1974, INT HISTOLOGICAL TYP, V11, P35
  • [5] Herle A J, 1975, J Clin Invest, V56, P272, DOI 10.1172/JCI108090
  • [6] JEEVANRAM RK, 1982, CANCER, V49, P2281, DOI 10.1002/1097-0142(19820601)49:11<2281::AID-CNCR2820491113>3.0.CO
  • [7] 2-1
  • [8] MAZAFERRI EL, 1977, MEDICINE, V56, P171
  • [9] MCWHIRTER WR, 1989, CANCER, V63, P2242, DOI 10.1002/1097-0142(19890601)63:11<2242::AID-CNCR2820631131>3.0.CO
  • [10] 2-V